Ironwood Pharmaceuticals | IRWD - Current Assets


Ironwood Pharmaceuticals reported $332.29M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.22B 128.53M Jun/2026
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Akebia Therapeutics USD 229.55M 13.93M Jun/2026
Almirall EUR 747.1M 33.12M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
Ardelyx USD 381.87M 447K Mar/2026
Astellas Pharma JPY 1.49T 63.68B Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
Charles River Laboratories USD 1.53B 40.3M Jun/2026
Coherus Biosciences USD 133.79M 72.25M Jun/2026
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
Ironwood Pharmaceuticals USD 332.29M 58.11M Mar/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Lexicon Pharmaceuticals USD 186.03M 84.14M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Moderna USD 5.82B 45M Jun/2026
Myriad Genetics USD 289M 23.8M Jun/2026
Pacira USD 615.21M 100.25M Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Sarepta Therapeutics USD 2.31B 228.06M Mar/2026
Takeda JPY 3.15T 59.77B Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025